

For further information, contact:

Dr. Robert B. Harris

President/CEO, CBI

Phone: 800 735 9224

Fax: 804 648 2641

**Commonwealth Biotechnologies, Inc. Announces Appointment of
Senior Vice President, Sales, Marketing, and Business Development**

*Joseph Chimera, Ph.D. will bring extensive experience in the life sciences business
development arena*

RICHMOND, VA (May 25, 2006) - Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market: CBTE), today announced that Dr. Joseph Chimera will be joining the company as Senior Vice President, Sales, Marketing, and Business Development. Dr. Chimera brings over 20 years experience in the life sciences services area which has been built upon outstanding graduate and post-graduate training in modern molecular biology. More specifically, he brings an extensive background in genomics, clinical testing, and, most recently, informatics. He has been responsible for planning, launch, and management of several new business units in his previous positions and will be specifically charged with growing the commercial client base of CBI. Dr. Chimera will assume immediate oversight of CBI's sales, marketing, and business development activities.

"While CBI has established itself as a solid player in the government contracting arena, we have lagged in growing the commercial sector. Growth in the commercial sector is not only important for revenue growth in general but also for revenue balance between government and commercial clients and for the better margins achievable in the commercial sector. Dr. Chimera brings a unique mix of solid science and business development skills that will allow him to interface very effectively with both those responsible for product development and for pipeline management in the Pharma and

Biotech clients we seek,” said Richard J. Freer, Ph.D., Chairman and COO of CBI. “This is an outstanding new appointment for us and we are looking forward to Joe joining the management team at CBI,” he added.

“Joe lead expansion initiatives at a previous employer which transformed an \$8 million sales program into a \$24 million discrete business unit,” added Robert B. Harris, Ph.D., President and CEO of CBI. “He has helped develop and otherwise manage commercialization strategies for life-sciences related services. We are looking for Joe to bring the same measured levels of success to CBI that he brought to his former positions.”

“CBI’s core competencies can provide solutions to a broad range of commercial markets, including discovery research, companies focused on developing new therapeutics and suppliers of diagnostics tests and laboratory services. Our commercialization strategy will initially focus on short-term revenue growth by leveraging existing commercial customer relationships. Longer-term, we will focus on attracting customers from diverse markets within the life sciences research and development and healthcare industries,” said Dr. Chimera.

About CBI

Commonwealth Biotechnologies, Inc. is a solutions provider to the global biotechnology industry, academic institutions, government agencies, and pharmaceutical companies. It offers broad ranging expertise and a complete array of the most current analytical and synthetic chemistries and biophysical analysis technologies, many of which are not available from other commercial sources. CBI has crafted a stimulating, open environment where scientists collaborate among themselves and with our clients, take on interesting challenges and develop creative solutions. Through its FIL division, CBI offers comprehensive genetic identity testing, including paternity, forensic, and CODIS analyses. CBI is accredited by the American Association of Blood Banks, CLIA, and the National Forensic Science Technology Council, and operates fully accredited BSL-3

laboratory. For more information, visit CBI on the web at www.cbi-biotech.com and visit FIL at www.fairfaxidlab.com.

#

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the Company's filings with the Securities and Exchange Commission. Specifically, there can be no assurances that new revenues will be generated as a result of enhanced marketing efforts. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities.